India
Centre Cuts Prices of 543 Cancer Medicines by Up to 93%, but Costly Immunotherapy Drugs Remain Unchanged
Revised prices offer substantial relief on several generic and biosimilar cancer medicines, while patient advocacy groups question exclusions that have left some expensive treatments unaffected.






